Managing endocrine-responsive breast cancer: Have all the necessary questions been asked to guide us forward?
Henning Mouridsen, MD, PhD
Copenhagen University Hospital
Copenhagen, Denmark
Reassessing adjuvant systemic therapy for early breast cancer
Michael Gnant, MD
Medical University of Vienna
Vienna, Austria
Anthracyclines as a component of adjuvant chemotherapy: For which patients is this necessary and appropriate?
Julie Gralow, MD
University of Washington School of Medicine
Seattle, Washington
Novel Strategies for the management of disease progression following standard chemotherapy
Angelo Di Leo, MD, PhD
Hospital of Prato, Istituto Toscano Tumori
Prato, Italy
HER2-amplified breast cancer: Refining our approach to acheive clinical outcomes
Joseph Gligorov, MD
Tenon Hospital
Paris, France
